GeoVax Labs, Inc. Provides Clinical Stud...( ATLANTA Aug. 5 /- GeoVax...)

ATLANTA, Aug. 5 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based HIV/AIDS vaccine development company, today announced updates on its ongoing and planned human clinical trials.

"We have two main areas of focus for our HIV/AIDS vaccine - preventative and therapeutic," stated Robert McNally, Ph.D., Chief Executive Officer and President of GeoVax Labs, Inc. "The results of the early Phase 1 clinical work for the preventative version of the vaccine have allowed the company to move up to another level of analysis, Phase 2a human clinical trial. This trial was initiated by the HIV Vaccine Trials Network (HVTN) in February this year and we are pleased to report that the HVTN has currently enrolled 30% of the projected participants. On the therapeutic front, we are in the midst of planning the details of a Phase 1 human clinical trial and expect to begin this trial, assuming FDA approval, in the first quarter of 2010."

Preventative Clinical Trials - Phase 2a

The preventative trial, designated as HVTN 205, is being conducted by the HVTN. The HVTN, funded and supported by the National Institutes of Allergy and Infectious Diseases (NIAID), is the largest worldwide clinical trials network dedicated to the development and testing of HIV/AIDS vaccines. The HVTN has sponsored over 80 Phase 1 trials for the initial evaluation of safety and immunogenicity of candidate HIV/AIDS vaccines. The results of these trials have merited only five phase 2 trials. Progressing to Phase 2 is a significant step for GeoVax. The first injections for the Phase 2a trial were conducted at the HVTN network sites at the University of Alabama, Birmingham, and Vanderbilt University, Nashville.

The trial is still expected to include a total of 225 volunteers (150 vaccine recipients and 75 placebo recipients) and take place at 13 HVTN sites: 11 in North Am
'/>"/>